drugset / Trial / NCT02148913
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma is feasible and safe.
Timeline
- Start
- 2014-06
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carfilzomib | Other / unclassified | 15 mg/m2 | Intravenous |
| Comparator | Carfilzomib | Other / unclassified | 20 mg/m2 | Intravenous |
| Comparator | Carfilzomib | Other / unclassified | 27 mg/m2 | Intravenous |
| Comparator | Bendamustine | Small molecule | 100 mg/m2 | — |
| Comparator | Melphalan | Small molecule | 100 mg/m2 | — |
| Comparator | Melphalan | Small molecule | 140 mg/m2 | — |